Recombinant Human HRAS/GTPase Hras Protein (His Tag)
| Code | Size | Price |
|---|
| PKSH030919-100ug | 100ug | £723.00 |
Quantity:
| PKSH030919-1mg | 1mg | £4,283.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Shipping:
This product is provided as lyophilized powder which is shipped with ice packs.
Storage:
Samples are stable for up to twelve months from date of receipt at -70°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Further Information
Abbreviation:
HRAS;GTPase Hras
Accession:
P01112
Background:
HRas, also known as HRAS, belongs to the small GTPase superfamily, Ras family and is widely expressed. It functions in signal transduction pathways. HRas can bind GTP and GDP, and they have intrinsic GTPase activity. It undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS). FCSS is arare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities, tumor predisposition, skin and musculoskeletal abnormalities. Defects in HRAS also can cause congenital myopathy with excess of muscle spindles. HRAS deficiency may be a cause of susceptibility to Hurthle cell thyroid carcinoma. It has been shown that defects in HRAS can cause susceptibility to bladder cancer which is a malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Defects in HRAS are the cause of oral squamous cell carcinoma.
Calculated MW:
22.4 kDa
Endotoxin:
< 1.0 EU per ug of the protein as determined by the LAL method.
Expression Host:
Baculovirus-Insect Cells
Formulation:
Lyophilized from sterile 50mM Tris, 100mM NaCl, pH 8.0, 10% glycerol
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Fusion tag:
C-His
ObservedMW:
23 kDa
Purity:
> 94 % as determined by reducing SDS-PAGE.
Sequence:
Met 1-Cys 186
Target Synonym:
C-BAS/HAS;C-H-RAS;C-HA-RAS1;CTLO;H-RASIDX;HAMSV;HRAS1;p21ras;RASH1
UNIProt ID:
P01112